Baxter International | BAX - Loan Capital


Baxter International reported $8.62B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Abbott USD 29.64B 19.74B Mar/2026
AngioDynamics USD 5.6M 100K Sep/2025
Artivion USD 215.35M 2.46M Mar/2026
AtriCure USD 61M 865K Mar/2026
Avanos Medical USD 87.3M 3M Mar/2026
Baxter International USD 8.62B 852M Mar/2026
Becton, Dickinson and Co. USD 14.71B 2.21B Mar/2026
Boston Scientific USD 11.01B 19M Dec/2025
Cooper Companies USD 1.86B 17.7M Mar/2026
Dexcom USD 1.3B 54.4M Mar/2026
Edwards Lifesciences USD 600M 1.7M Mar/2026
Fresenius EUR 9.22B 1.58B Dec/2025
Globus Medical USD 436K 9K Dec/2025
Halozyme Therapeutics USD 1.94B 206.73M Mar/2026
ICU Medical USD 1.26B 4.09M Mar/2026
Inogen USD 0 0 Jun/2022
Insulet USD 929.5M 1.3M Mar/2026
Integra LifeSciences USD 1.83B 29.45M Mar/2026
Intuitive Surgical USD 0 0 Mar/2025
J&J USD 37.53B 1.91B Mar/2026
Laboratory Of America USD 5.9B 748.3M Mar/2026
Masimo USD 445.7M 72.3M Mar/2026
Medtronic USD 27.88B 255M Dec/2025
Merit Medical Systems USD 735.16M 1.12M Mar/2026
Quest Diagnostics USD 5.16B 12M Mar/2026
Smith & Nephew USD 3.3B 22M Dec/2025
Stryker USD 14.22B 635M Mar/2026
Tandem Diabetes Care USD 601.77M 291.73M Mar/2026
Teleflex USD 2.51B 27.18M Mar/2026
Terumo JPY 99.91B 13M Mar/2026
Zimmer Biomet Holdings USD 6.3B 636.9M Mar/2026